Table 1.

Characteristics of the study population (n = 3,562)

Cases (n = 1,600)Controls (n = 1,962)P*
Tumor site, n (%)
    Proximal791 (49)
    Distal771 (48)
    Unknown38 (3)
Age at diagnosis or selection (range, 30-79), y64.9 ± 9.865.0 ± 10.20.86
Sex, n (%)
    Men897 (56)1,036 (53)
    Women703 (44)926 (47)0.05
Race/ethnicity, n (%)
    Non-Hispanic White1,462 (91)1,825 (93)
    Other138 (9)137 (7)0.05
Recent PMH use, postmenopausal women, n (%)
    No467 (77)549 (69)
    Yes143 (23)242 (31)<0.01
Kilocalories
    Men2,773 ± 1,2172,638 ± 1,1620.01
    Women2,046 ± 8741,974 ± 8320.09
TSER genotype, n (%)
    3/3 repeats488 (30)542 (28)
    3/2 repeats764 (48)983 (50)
    2/2 repeats348 (22)437 (22)0.16
Frequency, 2 repeat allele§0.460.480.15
TS 3'UTR 1494delTTAAAG genotype, n (%)
    ins/ins720 (45)881 (45)
    ins/del690 (43)866 (44)
    del/del190 (12)215 (11)0.65
Frequency, del allele§0.320.320.77
MTR D919G genotype, n (%)
    DD1,015 (63)1,264 (64)
    DG529 (33)608 (31)
    GG56 (4)90 (5)0.15
Frequency, G allele§0.200.200.97
RFC 80G>A genotype, n (%)
    GG513 (32)585 (30)
    GA788 (49)976 (50)
    AA299 (19)401 (20)0.24
Frequency, A allele0.430.450.10
TS haplotype, estimated (expected),
    3 repeat/ins0.30 (0.36)0.28 (0.35)
    3 repeat/del0.24 (0.17)0.24 (0.17)
    2 repeat/ins0.38 (0.31)0.40 (0.33)
    2 repeat/del0.08 (0.15)0.08 (0.15)0.56
  • * Based on χ2 or t test.

  • Mean ± SD.

  • Postmenopausal hormone use within 2 years of diagnosis/selection.

  • § Allele frequencies are reported for non-Hispanic Whites.

  • Maximum likelihood estimate (expected assuming linkage equilibrium).

  • P < 0.01 (χ2 test of linkage disequilibrium for cases or controls, separately).